公开(公告)号：US20240254110A1

公开(公告)日：2024-08-01

申请号：US18461253

申请日：2023-09-05

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Keith Jones ,  Carl Rye ,  Nicola Chessum ,  Matthew D. Cheeseman ,  Adele E. Pasqua ,  Kurt G. Pike ,  Paul F. Faulder

IPC: C07D405/12 ,  C07D319/18 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056

CPC classification number: C07D405/12 ,  C07D319/18 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US11814370B2

公开(公告)日：2023-11-14

申请号：US16339056

申请日：2017-10-06

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Matthew D. Cheeseman ,  A. Elisa Pasqua ,  Michael J. Tucker

IPC: C07D405/12 ,  C07B59/00 ,  A61P35/00

CPC classification number: C07D405/12 ,  C07B59/002 ,  A61P35/00 ,  C07B2200/05

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.

公开(公告)号：US20220220097A1

公开(公告)日：2022-07-14

申请号：US17406640

申请日：2021-08-19

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Carl Rye ,  Nicola Chessum ,  Matthew D. Cheeseman ,  Adele E. Pasqua ,  Kurt G. Pike ,  Paul F. Faulder

IPC: C07D405/12 ,  C07D405/14 ,  C07D319/18 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US11787786B2

公开(公告)日：2023-10-17

申请号：US17406640

申请日：2021-08-19

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Carl Rye ,  Nicola Chessum ,  Matthew D. Cheeseman ,  Adele E. Pasqua ,  Kurt G. Pike ,  Paul F. Faulder

IPC: C07D405/14 ,  A61K31/496 ,  A61P35/00 ,  C07D405/12 ,  C07D319/18 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056

CPC classification number: C07D405/12 ,  C07D319/18 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20200039965A1

公开(公告)日：2020-02-06

申请号：US16339056

申请日：2017-10-06

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Matthew D. Cheeseman ,  A. Elisa Pasqua ,  Michael J. Tucker

IPC: C07D405/12

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.